Showing posts with label control. Show all posts
Showing posts with label control. Show all posts

Tuesday, August 16, 2011

Test measuring blood glucose control may help predict risk of CVD events in patients with diabetes

ScienceDaily (July 25, 2011) — Measuring hemoglobin A 1c (HbA 1c ) levels in patients with diabetes is associated with improvement in models for predicting risk for cardiovascular disease (CVD), according to a report published Online First on July 25 by Archives of Internal Medicine, one of the JAMA/Archives journals.See Also:Health & MedicineDiabetesCholesterolWounds and HealingAsthmaMultiple Sclerosis ResearchDiseases and ConditionsReferenceDiabetic dietBlood sugarDiabetes mellitus type 2Hyperglycemia

According to background information in the article, diabetes has been recognized as a risk factor for CVD. But recent research indicates that the level of risk may vary among patients with diabetes. "Simulated cost-benefit analyses have suggested that this variability in CVD risk could provide an opportunity for tailored preventive therapy in diabetic patients," write the authors. They sought to investigate the predictive value of HbA 1c levels; this test reflects the average blood glucose level over the previous two to three months, and generally indicates how well the diabetes is being managed.

Nina P. Paynter, Ph.D., from Brigham and Women's Hospital, Boston, and colleagues, used data from participants of the Women's Health Study and the Physician's Health Study II. To generate the model, they included data from 24,674 women, of whom 685 had diabetes at baseline, and 11,280 men, of whom 563 had diabetes at baseline. Questionnaires provided participants' health history, and baseline blood samples were evaluated for cholesterol, C-reactive protein and HbA 1c levels. The researchers followed up participants for incident (new cases) CVD; women were followed up for a median (midpoint) of 10.2 years and men for a median of 11.8 years.

During follow-up, 125 cardiovascular events occurred in the 685 women with diabetes and 170 events occurred in the 563 men with diabetes (compared with 666 and 1,382 events, respectively, in participants without diabetes). In both sexes, including HbA 1c into risk modeling for CVD improved prediction of CVD compared to classification of all diabetic participants as high risk (10-year risk at least 20 percent). This association was especially pronounced in women. The risk modeling demonstrated that 71.9 percent of female diabetic participants had less than a 20 percent risk of CVD over 10 years, whereas only 24.5 percent of male diabetic participants had a predicted 10-year CVD risk of less than 20 percent. In models that included a term for HbA 1c , there was substantial improvement in CVD risk prediction for women, and more modest improvement in risk prediction for men. Using a yes/no term for diabetes instead of HbA 1c also improved prediction over classification as high risk in both men and women. In women, however, HbA 1c further improved prediction over the yes/no term.

"We found that in these large population-based cohorts of both men and women, presence of diabetes alone did not confer a 10-year risk of CVD higher than 20 percent, and measurement of HbA 1c level in diabetic subjects improved risk prediction compared with classification as cardiovascular risk equivalent," note the researchers. They propose that the difference in risk between the sexes may be partly attributed to the increase in CVD risk with age and the delayed risk in women. The authors call for further research to replicate their results, but conclude, "Our findings suggest that the improvement in CVD risk prediction, and possibly calibration, obtained with adding HbA 1c levels is highest in lower-risk populations."

This work was carried out with support from F. Hoffmann-La Roche Ltd; and grants from the National Heart Lung and Blood Institute, the National Cancer Institute and the Donald W. Reynolds Foundation, Las Vegas.


Commentary: Cardiovascular Risk Stratification, Hemoglobin A 1c , and the Tempo of Translation

An accompanying commentary by Mark J. Pletcher, M.D., M.P.H., from the University of California, San Francisco, notes that the Adult Treatment Panel III (ATP III) guidelines and other cardiovascular disease (CVD) prevention guidelines will be updated soon.

"One specific guideline refinement up for consideration this year is the approach to CVD risk stratification in patients with diabetes," writes Pletcher. He states that under current ATP III guidelines, diabetes is considered a "CHD

Friday, August 5, 2011

Patients who used mail-order pharmacy for new statin prescriptions achieved better cholesterol control, study finds

ScienceDaily (July 21, 2011) — Kaiser Permanente Northern California patients who obtained new statin prescriptions via a mail-order pharmacy achieved better cholesterol control in the first 3-15 months following the initiation of therapy -- compared to those patients who only obtained their statin prescription from their local Kaiser Permanente Northern California pharmacy.See Also:Health & MedicinePharmacologyToday's HealthcareCholesterolDiseases and ConditionsWounds and HealingDiabetesReferencePharmacologyPediatricsCOX-2 inhibitorHypercholesterolemia

Greater adjusted rates of LDL-C control in mail-order pharmacy users were seen across all gender and race-ethnicity groups, according to the study that appears in the current online issue of the Journal of General Internal Medicine.

After adjustment for demographic, clinical, and socioeconomic characteristics, as well as for potential unmeasured differences between mail-order and in-person pharmacy users, 85 percent of patients who used the mail-order pharmacy achieved target cholesterol levels, compared to 74.2 percent of patients who only used the local Kaiser Permanente pharmacy.

Previous studies have shown that mail-order pharmacy use is associated with greater medication adherence. However, this is the first study to examine whether mail-order pharmacy use is related to improved cardiovascular risk factor outcomes, according to Julie Schmittdiel, PhD, an investigator with the Kaiser Permanente Division of Research in Oakland, Calif., and the lead author of the study.

"While the findings of this study should be confirmed in a randomized controlled trial, they provide new evidence that mail-order pharmacy use may be associated with improved care and outcomes for patients for risk factors with cardiovascular disease," Schmittdiel said.

"Though mail order may not be right for all patients, this study shows that it is one possible tool in the broader health care system-level toolbox that can help patients meet their medication needs."

At Kaiser Permanente, members have 24/7 access to online pharmacy and pharmacy refills at kp.org using My Health Manager, which can be mailed to them free of shipping charges or made available for pick-up at any Kaiser Permanente pharmacy.

In comparing the effectiveness of mail-order pharmacy vs. local pharmacy use on cholesterol control in new statin users, investigators tapped a study population of 100,298 Kaiser Permanente members who were statin users between Jan. 1, 2005, and Dec. 31, 2007. Statin use was obtained from automated pharmacy records and patients were considered to be new users if they had not recorded use of statin in records prior to the initial statin prescription date.

Greater adherence to these medications by mail-order pharmacy users may reflect improved access to medications, researchers explain. Mail order does not require travel to the local pharmacy, which may provide ease and convenience for patients refilling medications. To address possible selection biases -- for example, the possibility that patients who use mail-order pharmacy services are more motivated to take care of their health than patients who do not use such services -- researchers conducted additional analyses.to minimize such biases. All analyses, even those accounting for such potential differences, showed a positive, significant association between mail order pharmacy use and cholesterol control.

This study is part of an ongoing body of work analyzing the impact of mail-order pharmacy use on clinical outcomes, and seeks to further understand how health care systems can work with patients to optimize medication use without compromising patient choice or safety.

In a January 2010 study in the American Journal of Managed Care, researchers from UCLA and the Kaiser Permanente Division of Research found that patients with diabetes, high blood pressure or high cholesterol who ordered their medications by mail were more likely to take them as prescribed by their doctors than did patients who obtained them from the local pharmacy.

Additional authors on the Journal of General Internal Medicine study include Andrew J. Karter, PhD; Wendy Dyer, MS; Melissa Parker, MS; and Connie Uratsu, all with the Kaiser Permanente Division of Research. James Chan, PharmD, PhD, with the Kaiser Permanente Pharmacy Outcomes and Research Group, and O.Kenrik Duru, MD, MSHS, with the UCLA David Geffen School of Medicine, also are co-authors. Funding was provided by the Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive Kidney Diseases.

Email or share this story: